Rawlins MD. 1995. Pharmacovigilance: Paradise lost, regained or postponed? J R Coll Physicians Lond 29:41–49.
Rossi AC, Knapp DE. 1984. Discovery of new adverse drug reactions. A review of the Food and Drug Administration’s spontaneous reporting system. J Am Med Assoc 252:1030–1033.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized control trial. J Am Med Assoc 288:321–333.
Rothman KJ, Greenland S. 1998. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven.
Sachs RM, Bortnichak EA. 1986. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 81:49–55.
Sackett DL, Haynes RB, Tugwell P. 1991. Deciding whether your treatment has done harm. In: Sackett DL, ed. Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed. Boston: Little Brown.
Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG, Juergens JP, Faich GA. 1987. Rhode Island physicians’ recognition and reporting of adverse drug reactions. R I Med J 70:311–316.
Skjeldestad FE, Amundsen T, Hoibraaten E. 2000. Reporting of adverse drug reactions to the Norwegian Medicines Control Agency—A discipline with few participants. Tidsskr Nor Laegeforen 120:336–338.
Stolley PD. 1990. How to interpret studies of adverse drug reactions. Clin Pharmacol Ther 48:337–339.
Strom BL, Tugwell P. 1990. Pharmacoepidemiology: Current status, prospects, and problems. Ann Intern Med 113:179–181.
Tegtmeier M, Harnischfeger G. 1994. Methods for the reduction of thujone content in pharmaceutical preparations of Artemisia, Salvia and Thuja. Eur J Pharm Biopharm 40:337–340.
Temple R. 1999. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. J Am Med Assoc 281:841–844.
Temple RJ, Jones JK, Crout JR. 1979. Adverse effects of newly marketed drugs. N Engl J Med 300:1046–1047.
Walker A. 2000. The Relation between Voluntary Notification and Material Risk in Dietary Supplement Safety. FDA Commissioned Paper. FDA Docket 00N-1200(41).
Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M. 2001. Comparison of German St. John’s wort products according to hyperforin and total hypericin content. J Am Pharm Assoc 41:560–566.